|
Consolidated Statements of Operations (Unaudited) (USD $)
|
3 Months Ended | |
|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
|
| OPERATING EXPENSES | ||
| General and administrative | $ 163,516us-gaap_GeneralAndAdministrativeExpense | $ 57,777us-gaap_GeneralAndAdministrativeExpense |
| Professional fees | 175,243us-gaap_ProfessionalFees | 384,215us-gaap_ProfessionalFees |
| Research and development | 2,839,801us-gaap_ResearchAndDevelopmentExpense | 1,352,356us-gaap_ResearchAndDevelopmentExpense |
| Salaries and wages | 745,427us-gaap_SalariesAndWages | 227,145us-gaap_SalariesAndWages |
| Total Operating Expenses | 3,923,987us-gaap_OperatingExpenses | 2,021,493us-gaap_OperatingExpenses |
| OPERATING LOSS | (3,923,987)us-gaap_OperatingIncomeLoss | (2,021,493)us-gaap_OperatingIncomeLoss |
| OTHER INCOME (EXPENSE) | ||
| Interest expense | (433)us-gaap_InterestExpense | (513)us-gaap_InterestExpense |
| Change in fair value of contingent consideration | (683,386)ohrp_ChangeInFairValueOfContingentConsideration | |
| Share in losses on investment in joint venture | (26,650)us-gaap_IncomeLossFromEquityMethodInvestments | |
| Interest income | 306us-gaap_InvestmentIncomeInterest | 81us-gaap_InvestmentIncomeInterest |
| Royalty income | 35,813us-gaap_RoyaltyIncomeNonoperating | |
| Total Other Income (Expense) | (674,350)us-gaap_NonoperatingIncomeExpense | (432)us-gaap_NonoperatingIncomeExpense |
| LOSS FROM OPERATIONS BEFORE INCOME TAXES | (4,598,337)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | (2,021,925)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest |
| NET LOSS | $ (4,598,337)us-gaap_NetIncomeLoss | $ (2,021,925)us-gaap_NetIncomeLoss |
| BASIC AND DILUTED LOSS PER SHARE | $ (0.18)us-gaap_EarningsPerShareBasicAndDiluted | $ (0.10)us-gaap_EarningsPerShareBasicAndDiluted |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: | ||
| BASIC AND DILUTED | 25,259,154us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted | 19,872,539us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
| X | ||||||||||
|
- Definition
The fair value adjustment for contingent consideration during period. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expenditures for salaries other than officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|